Strontium Ranelate雷尼酸锶,135459-

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Strontium Ranelate

CAS No. : 135459-87-9

MCE 国际站：Strontium Ranelate

产品活性：Strontium Ranelate (S12911) 是一种抗骨质疏松活性分子，其作用是通过减少骨吸收并促进骨形成，从而诱导正骨平衡。Strontium Ranelate 还可以激活非骨骼细胞中的钙敏感受体 (CaSR)，从而导致肌醇 1、4、5-三磷酸生成和丝裂原活化的蛋白激酶信号转导。

研究领域：GPCR/G Protein

作用靶点：CaSR

In Vitro: Strontium Ranelate (0.1-1 mM; 22 days; Mouse calvaria cells) treatment shows the expression of mRNA for early osteoblast markers (alkaline phosphatase, ALP) is visualized by day 5, while late markers (osteocalcin, OCN) are detectable only by day 15 and beyond.
Strontium Ranelate (0.1-1 mM; 22 days; Mouse calvaria cells) treatment results in significantly increases the mRNA expression of the osteoblastic markers ALP, BSP and OCN at day 22 of MC cell culture.
Strontium Ranelate is found to increase alkaline phosphatase activity and prostaglandin E2 production in a COX-2 dependent manner in murine marrow stromal cells.

In Vivo: Strontium Ranelate increases bone formation and decreased bone resorption, which results in increased bone mass in the vertebrae of intact adult mice.
In intact adult rats, Strontium Ranelate also increases bone mass, as measured by dual-energy X-ray absorptiometry, in lumbar vertebra and femur, and this is confirmed by histological assessment of trabecular bone volume in the tibial metaphysis.
Strontium Ranelate is found to decrease bone resorption and to increase bone formation in alveolar bone in normal adult monkeys (Macaca fascicularis), which exhibits extensive bone remodeling.
In ovariectomized rats, short-term (3 months) treatment with Strontium Ranelate prevents trabecular bone loss induced by oestrogen deficiency, as demonstrated by bone ash, bone mineral content and histomorphometric analysis in the tibial metaphysis. This effect results from decreased bone resorption while bone formation was maintained. These beneficial effects of Strontium Ranelate on bone mass and microarchitecture in ovariectomized rats are confirmed in long-term experiments. In this long-term study (2 years), the increase in bone mass and microarchitecture induced by Strontium Ranelate results in a marked improvement in bone strength, supporting the beneficial effect of this drug on bone resistance.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  NPS-2143  |  Etelcalcetide hydrochloride  |  Gadolinium chloride  |  Cinacalcet  |  Evocalcet  |  Calhex 231 hydrochloride  |  Tecalcet Hydrochloride  |  γ-L-Glutamyl-L-alanine  |  NPS 2390  |  Ligustroflavone  |  Upacicalcet sodium  |  Calcium-Sensing Receptor Antagonists I  |  SB-423562  |  Calindol hydrochloride  |  GSK3004774  |  AC-265347  |  CaSR antagonist-1  |  Gamma-Glu-Abu  |  SB-423557

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds